- Home
- » Tags
- » Sucroferric oxyhydroxide
Top View
- Therapeutic Class Overview Electrolyte Depleters
- Sucroferric Oxyhydroxide
- AKDC Prescription Formulary
- Phosphate Binders (Non-Calcium, Non-Aluminum) Lanthanum Carbonate, Sevelamer Carbonate, Ferric Citrate, Sucroferric Oxyhydroxide
- Product Monograph Including Patient Medication Information
- Velphoro, INN-Iron
- Innovationsreport 2017
- 1 Sucroferric Oxyhydroxide As Part of Combination Phosphate Binder
- Sucroferric Oxyhydroxide (Velphoro)
- Reimbursement Criteria for Frequently Requested Drugs
- VELPHORO® (Sucroferric Oxyhydroxide) Chewable Tablet
- Effectiveness of Sucroferric Oxyhydroxide in Patients
- New Brunswick Drug Plans Formulary
- Sucroferric Oxyhydroxide – Benefit Assessment According 1 to §35A Social Code Book V
- Phosphate Binders
- Medication Coverage Policy
- Sucroferric Oxyhydroxide Drug Monograph
- Intestinal Chelators, Sorbants, and Gut-Derived Uremic Toxins
- Velphoro (Sucroferric Oxyhydroxide) Basics Powered by Lowers Phosphate Levels
- Australian Public Assessment Report for Sucroferric Oxyhydroxide
- Sucroferric Oxyhydroxide (Control of Serum Phosphorus Levels in Paediatric Patients with CKD) – Benefit Assessment According to §35A Social Code Book V1
- 205109Orig1s000
- [Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
- Phosphate Binders Affect Vitamin K Concentration by Undesired Binding, an in Vitro Study A
- SUOMEN LÄÄKETILASTO S LT FINNISH STATISTICS on MEDICINES FSM 8 Keskeisiä Lukuja Lääkkeiden Myynnistä Ja Lääkekorvauksista Vuonna 2018
- Exploring Co-Dispensed Drug Use in Patients on Sevelamer Or Polystyrene Sulfonate to Identify Potential Novel Binding Interactions: a Cross Sectional in Silico Study
- Phosphate Binders in Patients with Chronic Kidney Disease
- Phosphate Binders Review – September 2020 Page 2 | Proprietary Information
- Velphoro, INN-Mixture of Polynuclear Iron(III)-Oxyhydroxide, Sucrose And
- New Phosphate Binders: What Do They Add?
- ATC Code Title
- Velphoro 500 Mg Chewable Tablets Iron As Sucroferric Oxyhydroxide
- Therapeutic Class Overview Phosphorus Depleters
- Chronic Renal Disease Program Reimbursable Drug Formulary – Feb 2021 Page 2 of 4 Generic Name Brand Name Reimbursable